Biohaven Ltd.
NYSE:BHVNBiotechnology
-$0.22 today
- Market cap
- $1.95B
- Beta
- 3.31
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$4.39
Volume 2.32M
Average 2.47M
BHVN Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Biohaven Ltd.NYSE: BHVN
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $4.63M rose 133.8% year over year, ahead of the +22.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 95.5% from the prior quarter. Over 3 fiscal years it compounded at +92.7% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +133.8% holds above the trailing-twelve-month pace of +22.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 9.92M USD
- Year-over-year change
- +26.3%
- 4-year CAGR
- +63.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.92M | +26.3% |
| FY2024 | 2024-12-31 | 7.86M | +13.6% |
| FY2023 | 2023-12-31 | 6.91M | +398.7% |
| FY2022 | 2022-12-31 | 1.39M | -0.5% |
| FY2021 | 2021-12-31 | 1.39M | — |
Depreciation & Amortization vs competitors
How BHVN compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +22.9% is the 3rd highest of 11, against a peer median of -1.2%.
- Over three fiscal years its annual growth of +92.7% compares with a peer median of +5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $32.16M USD | -7.6% | -4.5% | 47.4% | |
| LTM Mar 2026 | $12.61M USD | +0.4% | -1.4% | 4.0% | |
| LTM Jun 2026 | $10.67M USD | +22.9% | +92.7% | — | |
| LTM Mar 2026 | $9.99M USD | -2.7% | +28.1% | 15.1% | |
| LTM Sep 2026 | $3.73M USD | +10.4% | +5.3% | 3333.9% | |
| LTM Mar 2026 | $3.14M USD | -22.4% | -18.0% | 0.8% | |
| LTM Sep 2026 | $2.69M USD | -3.0% | +67.3% | — | |
| LTM Mar 2026 | $1.32M USD | +41.9% | +74.4% | — | |
| LTM Jun 2026 | $536K USD | +89.4% | — | — | |
| LTM Sep 2026 | €483K EUR | +19.4% | +39.9% | — | |
| LTM Mar 2026 | $39K USD | -69.3% | -10.5% | — | |
| Peer median (excluding BHVN) | — | -1.2% | +5.3% | 15.1% | |
Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.14M |
| Gross Profit | 0 | 0 | 0 | 0 | (4.14M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 181.49M | 437.07M | 373.28M | 795.87M | 635.07M |
| Selling, General & Admin | 37.41M | 130.86M | 62.77M | 89.24M | 106.17M |
| Operating Expenses | 218.9M | 567.93M | 436.05M | 885.11M | 741.24M |
| Depreciation & Amortization | 1.39M | 1.39M | 6.91M | 7.86M | 9.92M |
| EBITDA | (211.04M) | (568.46M) | (402.64M) | (837.83M) | (727.46M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (218.9M) | (567.93M) | (436.05M) | (885.11M) | (745.38M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 17.73M | 21.33M | 14.59M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 6.47M | (1.91M) | 26.5M | 39.42M | 8M |
| Income Before Tax | (212.43M) | (569.84M) | (409.55M) | (845.69M) | (737.38M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1.37M | 438K | (1.38M) | 735K | 1.44M |
| Net Income | (213.8M) | (570.28M) | (408.17M) | (846.42M) | (738.82M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (5.97) | (12.75) | (5.73) | (9.28) | (6.86) |
| EPS (Diluted) | (5.97) | (12.75) | (5.73) | (9.28) | (6.86) |
| Weighted Avg Shares | 35.82M | 44.74M | 71.2M | 91.23M | 107.62M |
| Weighted Avg Shares (Diluted) | 35.82M | 44.74M | 71.2M | 91.23M | 107.62M |
Biohaven Ltd.
NYSE:BHVN
Intrinsic Alpha fair value
Locked
Current Price
$12.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.